Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold |
as soon as is submitted to ZB.
Temsirolimus acts as additive with bendamustine in aggressive lymphoma.
Ann. Hematol. 95, 403-407 (2015)
The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway. It plays a pivotal role in the control of cell proliferation, survival, and angiogenesis with multiple and frequent dysregulations of this pathway in human tumors. Temsirolimus is an intravenous drug, specifically inhibiting the mTOR pathway. Bendamustine is well known for its clinical activity in indolent non-Hodgkin-lymphoma (NHL) and has lately shown clinical activity in mantle cell lymphoma (MCL). Here, we present a case report of temsirolimus in combination with bendamustine and rituximab leading to a CR in a pretreated male. In addition, our in vitro data underlines the additive and synergistic efficacy in cell growth reduction of temsirolimus combined with bendamustine in MCL cell lines and in DLBCL cell lines. Furthermore, as an underlying mechanism of this additive, effects on cell cycle inhibition and apoptosis induction could be identified.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
2.634
0.941
7
6
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Bendamustine ; Dlbcl ; Mcl ; Temsirolimus; Mantle Cell Lymphoma; Non-hodgkin-lymphoma; 1st-line Treatment; Plus Rituximab; Cycle Arrest; Mtor; Combination; Indolent; Trial; Multicenter
Language
english
Publication Year
2015
HGF-reported in Year
2016
ISSN (print) / ISBN
0939-5555
e-ISSN
1432-0584
Journal
Annals of Hematology
Quellenangaben
Volume: 95,
Issue: 3,
Pages: 403-407
Publisher
Springer
Publishing Place
New York
Reviewing status
Peer reviewed
Institute(s)
Institute of Functional Epigenetics (IFE)
POF-Topic(s)
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Research field(s)
Immune Response and Infection
PSP Element(s)
G-501411-001
WOS ID
WOS:000371605300006
Scopus ID
84949546767
PubMed ID
26658770
Erfassungsdatum
2016-12-31